journal article·2025-10-14Open access

Opportunities and Risks of Promoting Skin and Bone Healing via Implant Biofunctionalization of Extracellular Matrix Protein ECM1

Niklas R. Braun, Andreas K. Nüssler, Sabrina Ehnert

Journal of Functional Biomaterials· Volume 16· Issue 10

Abstract

Impaired bone regeneration and wound healing represent a major clinical and socioeconomic challenge for our aging and multimorbid population. Fracture and wound healing share many common features, with transforming growth factor beta (TGF-β) being a key regulator of inflammation, angiogenesis, fibroblast activation, and matrix remodeling. The dysregulation of TGF-β signaling is a hallmark of chronic wounds, excessive scar formation, and fracture non-union. Extracellular matrix protein 1 (ECM1) plays a crucial role in the activation of latent TGF-β. As a protein of the extracellular matrix, ECM1 offers ideal conditions for the biofunctionalization of bone implants or wound patches. Its mode of action has been studied mainly in fibrosis models of the liver or heart, where TGF-β acts as a driver of the disease. The controlled knock-out or overexpression of ECM1 either promoted or improved fibrosis development. In this review, we discuss how these findings can be applied to the biofunctionalization of implants to support bone and wound healing, considering the impact of TGF-β on the different healing phases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Connective tissue disorders research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Siegfried Weller Research Institute, BG Unfallklinik Tübingen, Department of Trauma and Reconstructive Surgery, University of Tübingen, Schnarrenbergstr. 95, 72076 Tübingen, Germany

References (96)

Show source-provided references
1. Epidemiology of adult fractures: A review10.1016/j.injury.2006.04.130 ↗
2. Development of a dynamic fall risk profile in elderly nursing home residents: A free field gait analysis based study10.1016/j.archger.2020.104294 ↗
3. Osteoporosis: Burden, health care provision and opportunities in the EU10.1007/s11657-011-0060-1 ↗
4. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019
5. Fracture healing: Mechanisms and interventions10.1038/nrrheum.2014.164 ↗
6. The risk of non-union per fracture: Current myths and revised figures from a population of over 4 million adults10.1080/17453674.2017.1321351 ↗
7. Increased therapy demand and impending loss of previous residence status after proximal femur fractures can be determined by continuous gait analysis—A clinical feasibility study10.1016/j.injury.2019.05.007 ↗
8. Pressure Ulcers in Elderly Patients with Hip Fracture Across the Continuum of Care10.1111/j.1532-5415.2009.02245.x ↗
9. Pressure sores and hip fractures10.1016/j.injury.2007.08.030 ↗
10. Prevalence of chronic wounds in the general population: Systematic review and meta-analysis of observational studies10.1016/j.annepidem.2018.10.005 ↗
11. Cost-of-illness studies in chronic ulcers: A systematic review10.12968/jowc.2017.26.Sup4.S4 ↗
12. Human Wound and Its Burden: Updated 2020 Compendium of Estimates10.1089/wound.2021.0026 ↗
13. Bone stimulation for fracture healing: What′s all the fuss?10.4103/0019-5413.50844 ↗
14. Delayed union and nonunions: Epidemiology, clinical issues, and financial aspects10.1016/j.injury.2014.04.002 ↗
15. Tissue repair and the dynamics of the extracellular matrix10.1016/j.biocel.2003.12.003 ↗
16. The Extracellular Matrix: Not Just Pretty Fibrils10.1126/science.1176009 ↗
17. Extracellular matrix and wound healing10.1016/j.patbio.2014.02.007 ↗
18. TGF-β: Regulation of extracellular matrix10.1038/ki.1992.81 ↗
19. Liarte, S., Bernabé-García, Á., and Nicolás, F.J. (2020). Role of TGF-β in Skin Chronic Wounds: A Keratinocyte Perspective. Cells, 9.10.3390/cells9020306 ↗
20. Critical Role of Transforming Growth Factor Beta in Different Phases of Wound Healing10.1089/wound.2012.0406 ↗
21. Gilbert, R.W., Vickaryous, M.K., and Viloria-Petit, A.M. (2016). Signalling by Transforming Growth Factor Beta Isoforms in Wound Healing and Tissue Regeneration. J. Dev. Biol., 4.10.3390/jdb4020021 ↗
22. Wound healing: An overview of acute, fibrotic and delayed healing10.2741/1184 ↗
23. Critical Review in Oral Biology & Medicine: Factors Affecting Wound Healing10.1177/0022034509359125 ↗
24. The Wound Healing Process: An Overview of the Cellular and Molecular Mechanisms10.1177/147323000903700531 ↗
25. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production10.1073/pnas.84.16.5788 ↗
26. Immunology of Wound Healing10.1007/s13671-018-0234-9 ↗
27. TGF-β in blood: A complex problem10.1016/S1359-6101(99)00037-4 ↗
28. Formation and Function of the Myofibroblast during Tissue Repair10.1038/sj.jid.5700613 ↗
29. Dual action of TGF-β induces vascular growth in vivo through recruitment of angiogenic VEGF-producing hematopoietic effector cells10.1007/s10456-012-9278-9 ↗
30. Angiogenesis in Wound Healing10.1046/j.1087-0024.2000.00014.x ↗
31. Wound Repair and Regeneration10.1159/000339613 ↗
33. The biology of fracture healing10.1016/j.injury.2011.03.031 ↗
34. Matrix metalloproteinase proteomics: Substrates, targets, and therapy10.1016/j.ceb.2009.06.006 ↗
35. Zhang, T., Wang, X.-F., Wang, Z.-C., Lou, D., Fang, Q.-Q., Hu, Y.-Y., Zhao, W.-Y., Zhang, L.-Y., Wu, L.-H., and Tan, W.-Q. (2020). Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. Biomed. Pharmacother., 129.10.1016/j.biopha.2020.110287 ↗
36. Ehnert, S., Zhao, J., Pscherer, S., Freude, T., Dooley, S., Kolk, A., Stöckle, U., Nussler, A.K., and Hube, R. (2012). Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): Possible mechanism for the failure of BMP therapy?. BMC Med., 10.10.1186/1741-7015-10-101 ↗
37. Negative regulation of TGF-β signaling in development10.1038/sj.cr.7290246 ↗
38. Silencing of TGF-β signalling by the pseudoreceptor BAMBI10.1038/46794 ↗
39. BAMBI Elimination Enhances Alternative TGF-β Signaling and Glomerular Dysfunction in Diabetic Mice10.2337/db14-1397 ↗
40. Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis10.1111/wrr.12398 ↗
41. Systematic analysis of binding of transcription factors to noncoding variants10.1038/s41586-021-03211-0 ↗
42. Interaction of Extracellular Matrix Protein 1 with Extracellular Matrix Components: ECM1 Is a Basement Membrane Protein of the Skin10.1038/sj.jid.5701231 ↗
43. ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum albumin subdomain-like 2 domain10.1016/j.matbio.2009.02.003 ↗
44. A Sporadic Family of Lipoid Proteinosis with Novel ECM1 Gene Mutations10.2147/CCID.S452127 ↗
45. ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-1 activation10.1136/gutjnl-2024-333213 ↗
46. Extracellular Matrix and Dermal Fibroblast Function in the Healing Wound10.1089/wound.2014.0561 ↗
47. Extracellular matrix contribution to skin wound re-epithelialization10.1016/j.matbio.2018.01.002 ↗
48. Extracellular matrix protein 1, a direct targeting molecule of parathyroid hormone-related peptide, negatively regulates chondrogenesis and endochondral ossification via associating with progranulin growth factor10.1096/fj.201600261R ↗
49. Hardy, S.A., Mabotuwana, N.S., Murtha, L.A., Coulter, B., Sanchez-Bezanilla, S., Al-Omary, M.S., Senanayake, T., Loering, S., Starkey, M., and Lee, R.J. (2019). Novel role of extracellular matrix protein 1 (ECM1) in cardiac aging and myocardial infarction. PLoS ONE, 14.10.1371/journal.pone.0212230 ↗
50. The extracellular matrix at a glance10.1242/jcs.023820 ↗
51. Cerebral small vessel disease-related protease HtrA1 processes latent TGF-β binding protein 1 and facilitates TGF-β signaling10.1073/pnas.1418087111 ↗
52. TGFβ stimulated re-epithelialisation is regulated by CTGF and Ras/MEK/ERK signalling10.1016/j.yexcr.2007.09.001 ↗
53. Role of active and latent transforming growth factor β in bone formation10.1002/jcb.240550312 ↗
54. Mechanisms of TGF-beta signaling from cell membrane to the nucleus10.1016/S0092-8674(03)00432-X ↗
55. Latent TGF-β structure and activation10.1038/nature10152 ↗
56. Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload10.1182/blood-2011-09-377648 ↗
57. TGF-β1 as a marker of delayed fracture healing10.1016/j.bone.2005.02.011 ↗
58. The effect and correlation of smoking with platelet indices, neutrophil lymphocyte ratio and platelet lymphocyte ratio10.1016/j.htct.2020.07.006 ↗
59. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β10.1046/j.1365-2893.2001.00314.x ↗
60. Gressner, A.M., Weiskirchen, R., Breitkopf, K., and Dooley, S. (2002). Roles of TGF-beta in hepatic fibrosis. Front. Biosci., 7.10.2741/A812 ↗
61. Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis10.1155/2016/3694957 ↗
62. Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease
63. Transforming growth factor beta1 from endometriomas promotes fibrosis in surrounding ovarian tissues via Smad2/3 signaling†10.1093/biolre/iox140 ↗
64. Factors circulating in the blood of type 2 diabetes mellitus patients affect osteoblast maturation—Description of a novel in vitro model10.1016/j.yexcr.2014.12.011 ↗
65. Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-β10.1007/s00109-012-0948-2 ↗
66. Transforming Growth Factor β in Tissue Fibrosis10.1056/NEJM199411103311907 ↗
67. Serum TGF-Beta 1 and TNF-Alpha Levels and Cardiac Fibrosis in Experimental Chronic Renal Failure10.1081/IMM-55807 ↗
68. TGFβ, cardiac fibroblasts, and the fibrotic response10.1016/j.cardiores.2006.07.012 ↗
69. TGF-β1 impairs mechanosensation of human osteoblasts via HDAC6-mediated shortening and distortion of primary cilia10.1007/s00109-017-1526-4 ↗
70. Accelerated Healing of Incisional Wounds in Rats Induced by Transforming Growth Factor-β10.1126/science.2442813 ↗
71. Le, M., Naridze, R., Morrison, J., Biggs, L.C., Rhea, L., Schutte, B.C., Kaartinen, V., and Dunnwald, M. (2012). Transforming Growth Factor Beta 3 Is Required for Excisional Wound Repair In Vivo. PLoS ONE, 7.10.1371/journal.pone.0048040 ↗
72. Multiple Transforming Growth Factor-β Isoforms and Receptors Function during Epithelial-Mesenchymal Cell Transformation in the Embryonic Heart10.1159/000101315 ↗
73. Angiogenic sprouting is regulated by endothelial cell expression of Slug
74. Piera-Velazquez, S., Mendoza, F.A., and Jimenez, S.A. (2016). Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases. J. Clin. Med., 5.10.3390/jcm5040045 ↗
75. Differential Expression of Transforming Growth Factor-β Receptors I and II and Activation of Smad 3 in Keloid Fibroblasts10.1097/00006534-200108000-00022 ↗
76. Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring10.1242/jcs.108.3.985 ↗
77. Modulation of α-smooth muscle actin expression in fibroblasts by transforming growth factor-β isoforms: An in vivo and in vitro study10.1046/j.1524-475X.1996.40217.x ↗
78. Amplifying gene expression with RNA-targeted therapeutics10.1038/s41573-023-00704-7 ↗
79. Current strategies employed in the manipulation of gene expression for clinical purposes10.1186/s12967-022-03747-3 ↗
80. Delivery systems for gene therapy10.4103/0971-6866.112870 ↗
81. The Temporal Effects of Anti-TGF-β1, 2, and 3 Monoclonal Antibody on Wound Healing and Hypertrophic Scar Formation10.1016/j.jamcollsurg.2005.03.032 ↗
82. Tuning hierarchical architecture of 3D polymeric scaffolds for cardiac tissue engineering10.1080/17458080701713946 ↗
83. Therapeutic strategies for skin regeneration based on biomedical substitutes10.1111/jdv.15391 ↗
84. Mineral Coatings for Temporally Controlled Delivery of Multiple Proteins10.1002/adma.201100060 ↗
85. Biopolymeric Coatings for Local Release of Therapeutics from Biomedical Implants10.1002/advs.202207603 ↗
86. Saeed, S., Barkat, K., Ashraf, M.U., Shabbir, M., Anjum, I., Badshah, S.F., Aamir, M., Malik, N.S., Tariq, A., and Ullah, R. (2023). Flexible Topical Hydrogel Patch Loaded with Antimicrobial Drug for Accelerated Wound Healing. Gels, 9.10.3390/gels9070567 ↗
87. Thongpon, P., Tang, M., and Cong, Z. (2025). Peptide-Based Nanoparticle for Tumor Therapy. Biomedicines, 13.10.3390/biomedicines13061415 ↗
88. Therapeutic peptides and their delivery using lipid-based nanoparticles10.4103/tcmj.tcmj_321_24 ↗
89. ECM1 Prevents Activation of Transforming Growth Factor β, Hepatic Stellate Cells, and Fibrogenesis in Mice10.1053/j.gastro.2019.07.036 ↗
90. Zhang, D., Abulitipu, A., Pang, P., Bai, L., Liu, L., Tuerxunmaimaiti, S., Chen, W., Chen, S., Lv, H., and Fu, Y. (2025). ECM1 protects against liver steatosis through PCBP1-mediated iron homeostasis. Hepatology.10.1097/HEP.0000000000001402 ↗
91. ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway10.1038/s41420-022-00846-4 ↗
92. Extracellular matrix as a contextual determinant of transforming growth factor-b signaling in epithelial-mesenchymal transition and in cancer10.4161/19336918.2014.972788 ↗
93. Long noncoding RNA turnover10.1016/j.biochi.2015.03.001 ↗
94. Pharmacokinetics, pharmacodynamics and safety of aptamers10.1016/j.addr.2018.10.008 ↗
95. Argonaute proteins: Key players in RNA silencing10.1038/nrm2321 ↗
96. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: Synthetic siRNA or vector-based shRNA?10.1517/14712590903448158 ↗